Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.
Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease.
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Drugs@FDA
Interferon-beta1b for the treatment of multiple sclerosis.
Pediatric Multiple Sclerosis.
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.
The use of hematopoietic stem cells in autoimmune diseases.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population.
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence.
Effect of smoking on multiple sclerosis: a meta-analysis.
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
CinnoVex home page
Newly onset sinus bradycardia in the context of multiple sclerosis relapse.
Emerging Concepts on the Gut Microbiome and Multiple Sclerosis.
UCSF Seminar: "How do we get a myelinated brain? A new model for distribution of oligodendrocytes throughout the developing CNS"
Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and disease.
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Treating Post-traumatic Stress Disorder in Patients with Multiple Sclerosis: A Randomized Controlled Trial Comparing the Efficacy of Eye Movement Desensitization and Reprocessing and Relaxation Therapy.
The role of pre-morbid intelligence and cognitive reserve in predicting cognitive efficiency in a sample of Italian elderly.
[Prevalence of multiple sclerosis in the Region of Murcia].
Pages
« first
‹ previous
…
78
79
80
81
82
83
84
85
86
…
next ›
last »